Computer-Aided Drug Design is advancing to a new era. Recent developments in statistical modelling, including Deep Learning, Machine Learning and high throughput simulations, enable workflows and deductions not achievable 20 years ago. The key interaction for many small molecules is via bio-molecules. The interaction between a small molecule and a biological system therefore manifests itself at multiple time and length scales. While the human chemist quite intuitively grasps the concept of multiple scales, most of the computer technologies do not relate multiple scales easily. Therefore, numerous methods in the realm of computational sciences have been developed. However, up to now it was not clear that the problem of multiple scales is not only a mere matter of computational abilities but even more a matter of accurate representation. Because of the amount of already performed simulations at various scales, deep learning (DL) becomes a viable approach to speed up computations by approximating simulations in a data-driven way. However, to accurately approximate the physical (simulated) properties of a given compound, an accurate, uniform representation is mandatory. Therefore, the biochemical and pharmaceutical encoder (CARATE) is introduced. Furthermore, the regression and classification abilities of CARATE are evaluated against benchmarking datasets (ZINC, ALCHEMY, MCF-7, MOLT-4, YEAST, Enzymes, Proteins) and compared to other baseline approaches.